Articles

FDA Clears Lutonix 035 Drug Coated Balloon C.R. Bard Inc.

C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix 035 drug-coated balloon (DCB) catheter for percutaneous transluminal angioplasty (PTA) after pre-...

October 10, 2014—Mitralign Inc. reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation (TR). Prof. Dr. med. J. Schofer of the...

October 8, 2014 — New updates to the Society for Cardiovascular Angiography and Interventions (SCAI) appropriate use criteria (AUC) calculator tool will help healthcare providers in making...

Clinical trial results by Recover Right revealed a survival rate of 73 percent in the total patient population. Recover Right was an FDA-approved, prospective, multicenter, single arm study...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a...

More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).

Ekos for PE

Acute intermediate-risk pulmonary emboli (PE) in normotensive patients with right ventricle dysfunction present the clinician with a quandary. With a 3 percent mortality rate[1] — just shy of the...

Emboline Prosheath

While transcatheter aortic valve replacement (TAVR) is a paradigm shift in how valve disease is treated, one nagging safety issue that remains is TAVR’s stroke rate, which is higher than...

Earlier this year, the Barnes-Jewish Hospital at Washington University School of Medicine in St. Louis adopted the instant wave-Free Ratio (iFR) technology. The iFR modality is a pressure-derived...

September 29, 2014 — Before undergoing cardiac imaging procedures involving radiation, healthcare providers should help patients understand why the procedure is needed and its potential benefits...